Touchlight, a British biotech focused on enzymatic DNA production, has announced signing a non-exclusive patent license agreement with Pfizer. The worldwide deal will give Pfizer rights to Touchlight’s enzymatic doggybone DNA (dbDNA) patent portfolio for use in manufacture and commercialization of mRNA-based vaccines, therapeutics and gene therapies. dbDNA is a synthetic DNA vector and enzymatic…